论文部分内容阅读
目的探讨三氧化二砷联合化疗治疗难治性多发性骨髓瘤(MM)的疗效及其应用价值。方法对21例难治性MM采用三氧化二砷联合化疗(联合MOD、M2或VAD)方法,其中三氧化二砷10mg/d静脉滴注,共10d,同时采用MOD、M2或VAD方案化疗。于化疗前后行血常规、血清M蛋白、骨髓涂片、肝肾功能检查判断治疗效果及毒副作用。结果三氧化二砷联合化疗对难治性MM有效率为85.7%(其中显效38.1%,进步47.6%),无明显毒副作用。结论三氧化二砷联合化疗对难治性MM有较高的缓解率,可能是治疗MM较有希望的药物。
Objective To investigate the curative effect and application value of combination therapy of arsenic trioxide and refractory multiple myeloma (MM). Methods Twenty-one patients with refractory MM were treated with arsenic trioxide combined with chemotherapy (MOD, M2 or VAD). Arsenic trioxide (10mg / d) was given intravenously for 10 days, while MOD, M2 or VAD chemotherapy was used. Before and after chemotherapy in blood routine, serum M protein, bone marrow smears, liver and kidney function tests to determine the treatment effect and side effects. Results The combination of arsenic trioxide and refractory MM was 85.7% (38.1% effective, 47.6% improvement), with no obvious side effects. Conclusion Arsenic trioxide combined with chemotherapy has a higher remission rate for refractory MM, which may be a promising drug for the treatment of MM.